Pascal E. R. Girin - 01 Apr 2025 Form 4 Insider Report for ClearPoint Neuro, Inc. (CLPT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Apr 2025, 20:21:29 UTC
Prior SEC filing
03 Jan 2025
Next SEC filing
19 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Danilo D'Alessandro, by Power of Attorney for Pascal E. R. Girin

Key filing fact

Pascal E. R. Girin filed Form 4 for ClearPoint Neuro, Inc. (CLPT) on 02 Apr 2025.

Key facts

  • This page summarizes Pascal E. R. Girin's Form 4 filing for ClearPoint Neuro, Inc. (CLPT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 02 Apr 2025, 20:21.

Change

  • Previous filing in this sequence was filed on 03 Jan 2025.
  • Current net transaction value: +$6,242.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLPT transaction

Common Stock

Award

Transaction value
$6,242
Shares
+525
Change %
+0.7%
Price
$11.89
Shares after
75,018
Date
01 Apr 2025
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2025.

SEC remarks

Power of Attorney is attached to this Form 4 as Exhibit 24

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .